Events Partner Content Welcome to 1st Rare & Genetic Neurodegenerative Drug Dev... Developing R&G neurodegenerative therapies
Events Partner Content 2nd Mitochondria-Targeted Drug Development Summit Therapies for mitochondrial dysfunction
Events Partner Content 9th Annual Neurodegenerative Drug Development Summit Translate Neurodegenerative R&D Into the Clinic
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
